{
  "docId": "019de073-7cac-75f7-8c4d-c1df42c29745",
  "docSlug": "674201d8cef93b1820f78aa5772cd90f",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 36,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide outlines a clinical trial protocol for a drug candidate (PCN-101) targeting Treatment-Resistant Depression (TRD).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/17",
  "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745",
  "deckJsonHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745.json",
  "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.85,
        "x": 0.07,
        "y": 0.24
      },
      "kind": "diagram",
      "text": "Study timeline showing dosing at day 1 and primary endpoint at 24 hours.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "698a3ee9-35b8-493e-8710-9c8aa1a990c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.42,
        "x": 0.51,
        "y": 0.53
      },
      "kind": "list",
      "text": "Other Important Items: Data expected end of 2022, multi-site, Phase 1 bioequivalence study, Phase 1 DDI study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07139a38-1564-4e24-8938-9224bc3503ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.42,
        "x": 0.07,
        "y": 0.53
      },
      "kind": "list",
      "text": "Design Overview: 93 subjects, 3 arms, Placebo vs 30/60mg IV, MADRS endpoint, CADSS safety readout.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62e0568f-c9e1-45d7-80b1-64d0f92b6427",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.07,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Note: DDI = Drug-Drug Interaction",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26bc2338-9e8d-49fb-b144-8e722f1f1423",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Randomized Phase 2 study of PCN-101 expected to establish human proof-of-concept",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83340b01-c289-429e-9db8-76e0041932b2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "32f72ef9-fbb7-4944-bf00-c2184aff3904",
      "evidence": "The timeline visualization represents a clinical trial schedule.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}